Explains Pat Furlong, Founding President and CEO, "With its research budget growing tighter each year, the NIH can fund only a fraction of the many promising applications it receives. Currently, only those grants which score in the top percentiles are able to be funded. We are thrilled that we have been able to step in, since the launch of the End Duchenne Grant Program in 2009, and provide the bridge funding needed to continue critical research like Dr. Khurana's."
The End Duchenne Grant Award Program represents the first Duchenne specific bridging program and the first ongoing bridge funding program to be presented in the rare disease category. As a collaborative effort with the NIH, the selection strategy behind this award is very different than any other private research investment in Duchenne, yet the goal of this award remains consistent with all of PPMD's research initiatives: to advance promising research which will impact this generation affected by Duchenne.
Dr. Khurana looks forward to continuing his work upregulating utrophin and thanks the organization for their financial support: "Parent Project Muscular Dystrophy and University of Pennsylvania have a long history together. Receiving this End Duchenne Grant is a great affirmation that the Duchenne community believes in the work we are doing here. We are hopeful that this therapy will change the progression of Duchenne and help extend the lifespan and quality of life for all patients living with the disorder."
To learn more about Parent Project Muscular Dystrophy's End Du
|SOURCE Parent Project Muscular Dystrophy|
Copyright©2010 PR Newswire.
All rights reserved